Percutaneous Deep Vein Arterialisation (pDVA) with the LimFlow System offers a cost-effective and high-value alternative to traditional therapies or amputation, according to a recent study published in the Journal of Critical Limb Ischemia … Peter Schneider, professor of surgery at the University of California (San Francisco, USA) and co-author of the published article, said: “The cost-effectiveness analysis builds on recently published 12-month data from the PROMISE I study by showing that pDVA with the LimFlow System can be a high-value therapy alternative to the status quo for no-option CLTI patients … “This research highlights the health economic benefits of reducing amputations and the need to offer patients a better alternative worldwide.” … read more
LinkedIn:
LimFlow SA